Aubagio ‘slows brain atrophy in RRMS patients’
Aubagio ‘slows brain atrophy in RRMS patients’
Genzyme has announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing Aubagio was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing-remitting multiple sclerosis (RRMS)... Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/